Press release from Oncology Venture Sweden AB
Hoersholm, Denmark, October 8th 2016

Poster on Successful DRP prediction of cisplatin and vinorelbine in lung cancer presented at European Society of Medical Oncology (ESMO)

**Poster # 1187P: Multigene expression profile for predicting efficacy of cisplatin and vinorelbine in non-small cell lung cancer is presented in Hall E, today: October 8th 2016 at 13-14 CET at ESMO. Please see the attached Poster. For the related abstract – please refer to: the ESMO website [http://www.esmo.org/](http://www.esmo.org/) as previously announced.**

ESMO is the leading European professional organization for medical oncology. Comprising more than 13,000 oncology professionals from over 130 countries. ESMO is the society of reference for oncology education and information.

“**These data from two independent lung cancer studies clearly demonstrate the strength of our Drug Response Predictor for cisplatin. The DRP can identify the patients who benefit the most from chemotherapy with cisplatin and vinorelbine. The most sensitive group comprising 1/3 of all the patients have a five-fold higher chance of surviving 3 years,”** said Adjunct Professor Peter Buhl Jensen, M.D., CEO of Oncology Venture. “**Oncology Venture is running a Proof of Concept clinical trial with LiPlaCis (in which cisplatin is the active cancer drug), in breast cancer and our partner Cadila Pharmaceuticals Ltd. will bring the LiPlaCis product forward into four phase 2 programs and a phase 3 trial in breast cancer, “**Peter Buhl Jensen further commented.

ESMO venue: Bella Center, Center Boulevard 5, 2300 Copenhagen, Denmark.

Poster # 1187P:
Multigene expression profile for predicting efficacy of cisplatin and vinorelbine in non-small cell lung cancer will be presented in Hall E, October 8th 2016 at 13-14 CET.

For further information, please contact

**Ulla Hald Buhl, COO and Chief IR & Communications**
Mobile: +45 2170 1049
ubah@oncologyventure.com

**Or**

**Peter Buhl Jensen, CEO**
Mobile: +45 21 60 89 22
pjb@oncologyventure.com

This information is information that Oncology Venture Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on October 08, 2016.

**About the Drug Response Predictor - DRP™ screening tool**

Oncology Venture uses the MPI multi gene DRP™ to select those patients that by the gene signature in their cancer is found to have a high likelihood of response to the drug. The goal is to develop the drug for the right patients and by screening patients before treatment the response rate can be significantly increased. This DRP™ method builds on the comparison of sensitive vs. resistant human cancer cell lines including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP™ is based on messenger RNA.

**About Oncology Venture Sweden AB**

Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.

The current product portfolio: LiPlaCis for Breast Cancer, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma. LiPlaCis is being developed in four phase 2 trials and one phase 3 trial in collaboration with Cadila Pharmaceuticals Ltd.